IRIS UniCatt

Lombardi, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.045
EU - Europa 2.397
AS - Asia 2.267
SA - Sud America 466
AF - Africa 67
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 4
Totale 8.254
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.934
SG - Singapore 1.116
DE - Germania 512
CN - Cina 469
BR - Brasile 394
SE - Svezia 376
NL - Olanda 364
IT - Italia 320
FR - Francia 231
VN - Vietnam 180
PL - Polonia 146
IN - India 103
IE - Irlanda 102
GB - Regno Unito 94
FI - Finlandia 83
JP - Giappone 74
ID - Indonesia 73
CA - Canada 53
HK - Hong Kong 48
BD - Bangladesh 46
RU - Federazione Russa 40
MX - Messico 32
AR - Argentina 30
ES - Italia 25
BE - Belgio 23
IQ - Iraq 18
UA - Ucraina 17
ZA - Sudafrica 17
KR - Corea 16
PK - Pakistan 16
TR - Turchia 16
EC - Ecuador 12
LT - Lituania 12
AT - Austria 11
CH - Svizzera 10
CI - Costa d'Avorio 10
IR - Iran 10
MA - Marocco 10
VE - Venezuela 10
JO - Giordania 9
KE - Kenya 7
AE - Emirati Arabi Uniti 6
EG - Egitto 6
OM - Oman 6
SA - Arabia Saudita 6
CZ - Repubblica Ceca 5
IL - Israele 5
JM - Giamaica 5
KZ - Kazakistan 5
LB - Libano 5
SY - Repubblica araba siriana 5
TW - Taiwan 5
AL - Albania 4
AU - Australia 4
AZ - Azerbaigian 4
CL - Cile 4
DO - Repubblica Dominicana 4
MY - Malesia 4
NG - Nigeria 4
NZ - Nuova Zelanda 4
PA - Panama 4
PE - Perù 4
PY - Paraguay 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
BH - Bahrain 3
BO - Bolivia 3
BY - Bielorussia 3
CO - Colombia 3
DZ - Algeria 3
KG - Kirghizistan 3
LV - Lettonia 3
MD - Moldavia 3
CR - Costa Rica 2
DK - Danimarca 2
EU - Europa 2
GT - Guatemala 2
HR - Croazia 2
NP - Nepal 2
PH - Filippine 2
PS - Palestinian Territory 2
QA - Qatar 2
RO - Romania 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BW - Botswana 1
CY - Cipro 1
GE - Georgia 1
GH - Ghana 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
IM - Isola di Man 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LY - Libia 1
Totale 8.242
Salva come PNG Salva come JPEG
Città #
Singapore 655
Chandler 486
Amsterdam 358
Ashburn 309
San Jose 307
New York 168
Warsaw 135
Beijing 113
Dublin 99
Milan 85
The Dalles 82
Los Angeles 78
Tokyo 72
Ho Chi Minh City 65
Rome 65
Jakarta 64
Lauterbourg 63
San Mateo 55
Hefei 51
Helsinki 51
Boston 49
St Louis 48
Hanoi 47
Tukwila 47
Frankfurt am Main 43
Hong Kong 42
Marseille 42
Princeton 42
São Paulo 42
Wilmington 36
Dallas 31
Santa Clara 31
Orem 30
Fairfield 27
Nuremberg 27
Ann Arbor 26
Houston 26
Moscow 26
Council Bluffs 25
London 25
Munich 24
Nanjing 24
Brussels 23
Buffalo 23
Seattle 21
Woodbridge 21
Chicago 20
Paris 20
Turku 20
Brooklyn 19
Jacksonville 19
Denver 18
Atlanta 17
Chennai 17
Pune 17
Düsseldorf 16
Cambridge 15
Montreal 15
Toronto 15
Kent 14
Poplar 14
Seoul 14
Augusta 13
Cattolica 12
Redwood City 12
Guangzhou 11
Haiphong 11
Phoenix 11
Abidjan 10
Da Nang 10
Dearborn 10
Dhaka 10
Johannesburg 10
Mexico City 10
Stockholm 10
Amman 9
Hangzhou 9
Hyderabad 9
Lappeenranta 9
Mumbai 9
Boardman 8
Lahore 8
Ottawa 8
Roubaix 8
Turin 8
Andover 7
Curitiba 7
Nanchang 7
Queens 7
Rio de Janeiro 7
Tianjin 7
Vienna 7
Belo Horizonte 6
Buenos Aires 6
Columbus 6
Jinan 6
Manchester 6
Nairobi 6
North Bergen 6
Norwalk 6
Totale 4.801
Salva come PNG Salva come JPEG
Nome #
Functional associations between polymorphic regions of the human 3'IgH locus and COVID-19 disease 803
Evaluation of the effect of a floxed Neo cassette within the dystroglycan (Dag1) gene 348
Retinal capillary involvement in early post-COVID-19 patients: a healthy controlled study 202
Sarilumab use in severe SARS-CoV-2 pneumonia 164
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 162
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir–rilpivirine in clinical practice 152
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 151
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 148
HIV-Related Internalized Stigma and Patient Health Engagement Model in an Italian Cohort of People Living With HIV 148
Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database 141
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 139
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 139
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure 138
Psychological distress during the initial stage of the COVID-19 pandemic in an italian population living with HIV: An online survey 138
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 137
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 135
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice 135
Impact of the COVID-19 Pandemic on Health Care Is Negatively Associated With Psychosocial Well-Being in an Italian Cohort of People Living With HIV 132
HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report 131
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 130
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 130
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 129
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line 129
Seroprevalence of sars-cov-2 antibodies in hiv-infected patients in rome, italy during the covid-19 outbreak 126
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 125
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 121
Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice 121
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication 118
Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016 118
Use of Long-Acting Therapies for HIV Care in Italy: Are People Living with HIV Prepared for Change? A Cross-Sectional Study 117
The association between stigma and wellbeing in an Italian cohort of PLWH: The role of social support and personal factors 115
Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study 114
Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen 113
Home Care Assistance: Has Covid-19 had an Impact on the Complex Management of HIV Patients? 113
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 112
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed 111
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study 110
Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital 109
Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir-Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report 106
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 106
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 104
Evaluation of doravirine-based regimen population target in a large Italian clinical center 103
Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients 101
Clinical presentation of human monkeypox virus infection during the 2022 outbreak: descriptive case series from a large italian Research Hospital 101
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study 101
Implementing a Personalized Antimicrobial Stewardship Program for Women with Gynecological Cancers and Healthcare-Associated Infections 99
Characteristics of mental health interventions in a cohort of Italian PLWH over the last five years: impact of HIV disease and outbreak of COVID-19 pandemic 98
Real-Life Safety of Doravirine in Treatment-Experienced, Virologically Suppressed PLWHIV 96
Real World Data from an Italian Outpatient Clinical Setting and from Home Care Assistance of Treatment-Experienced PWH Switching to CAB + RPV Regimen: A Prospective Observational Study 95
Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting 95
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 94
No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy 94
Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors 91
Quantification of total hiv dna as a marker to measure viral reservoir: Methods and potential implications for clinical practice 91
Response to BNT162b2 mRNA COVID-19 vaccine of ART-experienced people living with HIV: a prospective analysis from a single-center study in Rome, Italy 85
Long-term maintenance of virologic suppression in native and migrant HIV-1 naïve patients: an Italian cohort study 84
A Conserved Glycan in the C2 Domain of HIV-1 Envelope Acts as a Molecular Switch to Control X4 Utilization by Clonal Variants with Identical V3 Loops 83
Short Communication: Efficacy and Safety of Dolutegravir plus Lamivudine as a First-Line Regimen in Clinical Practice 82
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 82
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 79
Still much to learn about the diagnostic role of SARS-CoV-2 antibody detection 78
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference 74
Assessing dengue seroprevalence among people living with HIV (PLWH) in rome, Italy: Insights from the 2023 Italian autochthonous outbreak 73
Compound heterozygosity for mutations in LMNA in a patient with a myopathic and lipodystrophic mandibuloacral dysplasia type A phenotype 69
Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy 63
Increased release and activity of matrix metalloproteinase-9 in patients with mandibuloacral dysplasia type A, a rare premature ageing syndrome 43
‘Leaving no stones unturned’: up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort 1
Totale 8.375
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.679
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.679
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202110 0 0 0 0 0 0 0 0 0 0 0 10
2021/2022483 12 3 10 52 11 7 38 78 14 44 60 154
2022/20231.220 168 187 97 181 75 143 66 94 137 8 52 12
2023/2024684 16 147 17 65 26 138 47 15 18 28 97 70
2024/20251.350 23 18 161 54 103 71 97 74 161 120 256 212
2025/20264.060 468 92 186 475 673 817 542 161 212 239 154 41
Totale 8.375